Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026GlobeNewsWire · 2 days ago
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?GuruFocus · 3 days ago
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWire · 3 days ago
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS TorontoGlobeNewsWire · 4 days ago
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026GlobeNewsWire · Oct 7, 2026
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Rated “Moderate Buy” by Sell-Side BrokeragesDefense World · Oct 3, 2026Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.68 | -$0.63 | Beat |
| May 12, 2026 | -$0.75 | -$0.66 | Beat |
| Mar 26, 2026 | -$0.85 | -$0.80 | Beat |
| Nov 12, 2025 | -$0.97 | -$0.85 | Beat |
| Aug 12, 2025 | -$1.00 | -$0.97 | Beat |
| May 13, 2025 | -$1.21 | -$1.03 | Beat |